PL2626420T3 - Polinukleotydy kodujące epitopy hTERT ograniczone do MHC klasy I HLA-B7, ich analogi lub poliepitopy - Google Patents

Polinukleotydy kodujące epitopy hTERT ograniczone do MHC klasy I HLA-B7, ich analogi lub poliepitopy

Info

Publication number
PL2626420T3
PL2626420T3 PL13165854T PL13165854T PL2626420T3 PL 2626420 T3 PL2626420 T3 PL 2626420T3 PL 13165854 T PL13165854 T PL 13165854T PL 13165854 T PL13165854 T PL 13165854T PL 2626420 T3 PL2626420 T3 PL 2626420T3
Authority
PL
Poland
Prior art keywords
polyepitopes
hla
analogues
mhc class
polynucleotides encoding
Prior art date
Application number
PL13165854T
Other languages
English (en)
Inventor
Pierre Langlade-Demoyen
Pons Fransisco Garcia
Olivier Adotevi
Sylvain Cardinaud
Christine Neuveut
Original Assignee
Institut Pasteur
Institut National De La Sante Et De La Recherche Medicale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut Pasteur, Institut National De La Sante Et De La Recherche Medicale filed Critical Institut Pasteur
Publication of PL2626420T3 publication Critical patent/PL2626420T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/1276—RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL13165854T 2005-07-29 2006-07-31 Polinukleotydy kodujące epitopy hTERT ograniczone do MHC klasy I HLA-B7, ich analogi lub poliepitopy PL2626420T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05291627A EP1748067A1 (en) 2005-07-29 2005-07-29 Polynucleotides encoding MHC class I-restricted hTERT epitopes, analogues thereof or polyepitopes

Publications (1)

Publication Number Publication Date
PL2626420T3 true PL2626420T3 (pl) 2017-01-31

Family

ID=35735256

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13165854T PL2626420T3 (pl) 2005-07-29 2006-07-31 Polinukleotydy kodujące epitopy hTERT ograniczone do MHC klasy I HLA-B7, ich analogi lub poliepitopy

Country Status (9)

Country Link
US (3) US8858931B2 (pl)
EP (3) EP1748067A1 (pl)
JP (4) JP5631545B2 (pl)
CA (1) CA2616674C (pl)
DK (2) DK2626420T3 (pl)
ES (2) ES2440768T3 (pl)
PL (1) PL2626420T3 (pl)
PT (1) PT2626420T (pl)
WO (1) WO2007014740A2 (pl)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10767167B2 (en) 2005-07-29 2020-09-08 Institut Pasteur Polynucleotides encoding MHC class I-restricted hTERT epitopes, analogues thereof or polyepitopes
EP1748067A1 (en) * 2005-07-29 2007-01-31 Institut Pasteur Polynucleotides encoding MHC class I-restricted hTERT epitopes, analogues thereof or polyepitopes
WO2008010010A1 (en) 2006-07-12 2008-01-24 Vaxon Biotech Identification, optimization and use of cryptic hla-b7 epitopes for immunotherapy
US20080171062A1 (en) * 2006-08-16 2008-07-17 Monica Sala-Schaeffer Recombinant HBsAg virus-like particles containing polyepitopes of interest, their production and use
CA2678404C (en) * 2007-02-28 2019-03-19 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Brachyury polypeptides and methods for use
HUE025636T2 (en) * 2007-07-27 2016-04-28 Immatics Biotechnologies Gmbh Novel immunogenic epitopes for immunotherapy
US7904566B2 (en) * 2008-03-14 2011-03-08 Silicon Image, Inc. Method, apparatus, and system for employing an enhanced port multiplier
US7979589B2 (en) * 2008-03-14 2011-07-12 Silicon Image, Inc. Method, apparatus, and system for port multiplier enhancement
RU2581800C2 (ru) 2010-02-16 2016-04-20 Ультимовакс Ас Полипептиды
WO2013136182A1 (en) 2012-03-15 2013-09-19 Macrocure, Ltd. Activated immunostimulatory cell composition and uses thereof
RU2014140795A (ru) 2012-03-15 2016-05-10 Макрокьюэ, Лтд. Активированная иммуностимулирующая клеточная композиция, используемая для лечения инфекционных заболеваний
EP2639299A1 (en) 2012-03-16 2013-09-18 Invectys Universal cancer peptides derived from telomerase
EP2899201B1 (en) * 2012-09-19 2019-09-11 Gemvax & Kael Co., Ltd. Cell penetrating peptide, conjugate comprising same, and composition comprising conjugate
US9453209B2 (en) * 2012-12-27 2016-09-27 Sierra Sciences, Llc Enhancing health in mammals using telomerase reverse transcriptase gene therapy
CA2908138A1 (en) 2013-03-28 2014-10-02 Invectys A cancer vaccine for cats
AU2014242916B2 (en) * 2013-03-28 2018-08-02 Invectys A cancer vaccine for dogs
GB201315946D0 (en) * 2013-09-06 2013-10-23 Immune Targeting Systems Its Ltd Oncology vaccine
EP3063280B1 (en) 2013-10-28 2019-08-14 Invectys Gene electrotransfer into skin cells
HUE047898T2 (hu) * 2013-10-28 2020-05-28 Invectys Telomerázt kódoló DNS vakcina
SG11201705721WA (en) 2015-01-14 2017-08-30 Brigham & Womens Hospital Inc Treatment of cancer with anti-lap monoclonal antibodies
WO2016145317A1 (en) 2015-03-12 2016-09-15 Thomas Schwaab Enrichment of cd16+ monocytes to improve dendritic cell vaccine quality
EP3283529B1 (en) 2015-04-17 2023-06-07 The General Hospital Corporation Agents, systems and methods for treating cancer
WO2017060360A1 (en) * 2015-10-06 2017-04-13 Invectys Polyepitope constructs for use in immunotherapy
GB201519557D0 (en) 2015-11-05 2015-12-23 Univ Witwatersrand Jhb Compounds for use in the treatment of telomere related diseases and/or telomere related medical conditions
CA2954892A1 (en) 2016-01-19 2017-07-19 Pfizer Inc. Immunogens derived from tumor-associated antigens or nucleic acid molecules encoding the immunogens
AU2017336088B2 (en) 2016-09-30 2023-07-06 Inovio Pharmaceuticals, Inc. Tert immunogenic compositions and methods of treatment using the same
EP3622078A1 (en) 2017-05-09 2020-03-18 Invectys Recombinant measles vaccine expressing htert
AU2018395397A1 (en) * 2017-12-28 2020-08-06 Gritstone Bio, Inc. Antigen-binding proteins targeting shared antigens
CN110305217B (zh) 2018-03-27 2022-03-29 广州爱思迈生物医药科技有限公司 双特异性抗体及其应用
EP3773690A1 (en) 2018-04-13 2021-02-17 INSERM (Institut National de la Santé et de la Recherche Médicale) New vaccinal strategy
MX2021002333A (es) * 2018-08-30 2021-04-28 Univ Montreal Metodo basado en proteogenomica para identificar antigenos especificos de tumores.
CN113105528B (zh) * 2020-01-13 2023-12-08 辽宁中健医药科技有限公司 一条肿瘤相关抗原ctl表位肽及其应用
AU2021294322A1 (en) * 2020-06-26 2023-02-02 National Breast Cancer Coalition Breast cancer vaccine
WO2022082030A2 (en) 2020-10-15 2022-04-21 Gritstone Bio, Inc. Antigen-binding proteins and related methods of use
WO2022155503A1 (en) 2021-01-14 2022-07-21 Gritstone Bio, Inc. Multi-specific antibodies and methods of use
CN118792176A (zh) * 2024-07-24 2024-10-18 佳吾益(北京)科技有限公司 用于mhc新抗原肽发现及亲和分析的工程化细胞
WO2026020513A1 (en) * 2024-07-24 2026-01-29 Jwe (Beijing) Science Technology, Inc. Engineered cell for identifing mhc neoantigens

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA199900355A1 (ru) * 1996-10-01 2000-08-28 Джерон Корпорейшн Теломераза обратная тринскриптаза
US7622549B2 (en) * 1997-04-18 2009-11-24 Geron Corporation Human telomerase reverse transcriptase polypeptides
US7413864B2 (en) * 1997-04-18 2008-08-19 Geron Corporation Treating cancer using a telomerase vaccine
KR100581990B1 (ko) * 1997-07-01 2006-05-23 캄비아 바이오시스템즈 엘엘씨 척추 동물 텔로머라제 유전자 및 단백질과 이의 용도
AU3456099A (en) * 1998-03-31 1999-10-18 Geron Corporation Methods and compositions for eliciting an immune response to a telomerase antigen
FR2777909B1 (fr) 1998-04-24 2002-08-02 Pasteur Institut Utilisation de sequences d'adn de structure triplex pour le tranfert de sequences de nucleotides dans des cellules, vecteurs recombinants contenant ces sequences triplex
US7030211B1 (en) * 1998-07-08 2006-04-18 Gemvax As Antigenic peptides derived from telomerase
ES2337429T3 (es) 1999-10-11 2010-04-23 Institut Pasteur Vectores lentivirales para la preparacion de composiciones inmunoterapeuticas.
HK1050210B (en) 1999-10-12 2007-08-24 Institut Pasteur Lentiviral triplex dna, and vectors and recombinant cells containing lentiviral triplex dna
FR2862648B1 (fr) 2003-11-21 2006-02-03 Biomerieux Sa Nouveau peptide immunogene et nouveaux epitopes et utilisations notamment dans la preparation de compositions pharmaceutiques actives contre le virus de l 'hepatite c
CA2504451A1 (en) * 2004-08-10 2006-02-10 Geron Corporation Dendritic cell vaccines for treating cancer made from embryonic stem cells
EP1748067A1 (en) 2005-07-29 2007-01-31 Institut Pasteur Polynucleotides encoding MHC class I-restricted hTERT epitopes, analogues thereof or polyepitopes

Also Published As

Publication number Publication date
JP6257667B2 (ja) 2018-01-10
US20100172878A1 (en) 2010-07-08
EP1910529B1 (en) 2013-10-16
JP5836202B2 (ja) 2015-12-24
US8858931B2 (en) 2014-10-14
US9624479B2 (en) 2017-04-18
JP2012183076A (ja) 2012-09-27
JP5931812B2 (ja) 2016-06-08
EP1910529A2 (en) 2008-04-16
EP2626420B1 (en) 2016-06-22
CA2616674C (en) 2018-09-04
US20140056932A1 (en) 2014-02-27
WO2007014740A2 (en) 2007-02-08
DK2626420T3 (en) 2016-09-26
EP1748067A1 (en) 2007-01-31
JP5631545B2 (ja) 2014-11-26
JP2013230164A (ja) 2013-11-14
PT2626420T (pt) 2016-09-28
ES2590462T3 (es) 2016-11-22
JP2016104031A (ja) 2016-06-09
DK1910529T3 (da) 2014-01-13
EP2626420A2 (en) 2013-08-14
JP2009502150A (ja) 2009-01-29
EP2626420A3 (en) 2013-10-30
US8003773B2 (en) 2011-08-23
US20090175892A1 (en) 2009-07-09
WO2007014740A3 (en) 2007-05-03
CA2616674A1 (en) 2007-02-08
ES2440768T3 (es) 2014-01-30

Similar Documents

Publication Publication Date Title
PT2626420T (pt) Polipéptidos que codificam epítopos de terth restritos à molécula hla-b7 da classe i do cph, os seus análogos ou poliepítopos
EG25263A (en) Fungicidal mixtures based on azolopyrimidinylamines.
DK1849470T4 (en) Cancerlægemiddel, som indeholder alpha, alpha, alpha-trifluorthymidin og thymidin-phosphorylase-inhibitor
EG25271A (en) Fungicidal combinations.
EG25126A (en) Steam reforming.
IL209963A0 (en) Epitope analogues
PT2878307T (pt) Composição imunogénica.
EP1910920A4 (en) CODE TRANSFORMATION
EG25121A (en) Steam reforming.
AP2281A (en) Novel compounds.
PT2468732E (pt) 1h-quinazolino-2,4-dionas e sua utilização como ligandos dos receptores ampa
EP1841430A4 (en) SUBSTITUTED PYRIDAZINYL AND PYRIMIDINYL-CHINOLIN-4-YLAMINE ANALOGUE
SI2221383T1 (sl) Nukleotidna sekvenca, ki kodira proti-glivični polipeptid
IL190538A0 (en) Two-part code
AP2337A (en) Motilide compounds.
EP1874979A4 (en) REACTOR
EP1723145A4 (en) SUBSTITUTED 5,12-DIAZENZOANTHRACENANALOGA
IL185408A0 (en) (+)-and(-)-8-alkyl-3-(trifluoralkylsulfonyloxy)-8-azabicycl (3.2.1)oct-2-ene
GB0516252D0 (en) The dive daemon
GB0507105D0 (en) Coding data
GB0504761D0 (en) Alfatie, Coliawel, Omaatie
AU4212P (en) Goldenlighthouse Banksia spinulosa var. collina
GB0500851D0 (en) C.f.m.
ZA200407886B (en) Locking arrangement.
GB0506690D0 (en) Authentication system